Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers

被引:0
|
作者
Malo, Sara [1 ]
Aguilar-Palacio, Isabel [1 ]
Feja, Cristina [1 ]
Menditto, Enrica [2 ]
Jesus Lallana, Maria [3 ]
Andrade, Elena [4 ,5 ]
Antonio Casasnovas, Jose [6 ]
Jose Rabanaque, Maria [1 ]
机构
[1] Univ Zaragoza, Dept Med Prevent & Salud Publ, Fdn Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain
[2] Univ Napoli Federico II, CIRFF, Naples, Italy
[3] IIS Aragon, Serv Aragones Salud, Zaragoza, Spain
[4] Univ Autonoma Madrid, Dept Med Prevent & Salud Publ, IdiPaz, Madrid, Spain
[5] CIBERESP, Madrid, Spain
[6] Univ Zaragoza, Dept Med Psiquiatria & Dermatol, Fdn Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2018年 / 71卷 / 01期
关键词
Discontinuation; Lipid-lowering drug; Pharmacoepidemiology; Medication; Measurement; Cardiovascular disease; Primary prevention; DENSITY-LIPOPROTEIN CHOLESTEROL; THERAPY; POPULATION; RISK;
D O I
10.1016/j.recesp.2017.03.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: The aim of this study was to assess patterns of treatment persistence in a cohort of male Spanish workers receiving statin therapy for primary prevention of cardiovascular disease. Methods: This descriptive study was conducted within the framework of the prospective longitudinal Aragon Workers' Health Study (N = 5400). Incident male statin users were identified based on data collected from the regional government's medication consumption information system. Patterns of treatment persistence with statins prescribed for primary cardiovascular disease prevention were assessed and, the relevance of potential predictors explored. Results: Among the 725 new statin users, less than one third remained persistent during the 1 year of follow-up. About 15% of nonpersistent users discontinued statin therapy after dispensation of the first prescription; of these, 42.1% did not recommence treatment within the following year. Factors reducing the likelihood of treatment discontinuation were older age (HR, 0.55; 95%CI, 039-0.77) and cotreatment with antihypertensive drugs (HR, 0.68; 95%CI, 0.56-0.82). No association was observed between treatment persistence and cotreatment with antidiabetic or antithrombotic drugs, baseline low-density lipoprotein levels, or total cholesterol levels. However, persistence was influenced by the type of statin first prescribed. Conclusions: Our analysis of a cohort of healthy male workers revealed poor statin persistence. These findings underscore the need for a better understanding of patterns of statin use, especially in apparently healthy individuals, and for the incorporation of patient behavior into prescribing decisions. (C) 2017 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 50 条
  • [21] Statins for Primary Prevention of Cardiovascular Disease Review of Evidence and Recommendations for Clinical Practice
    Kazi, Dhruv S.
    Penko, Joanne M.
    Bibbins-Domingo, Kirsten
    MEDICAL CLINICS OF NORTH AMERICA, 2017, 101 (04) : 689 - +
  • [22] Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks
    Minder, C. Michael
    Blumenthal, Roger S.
    Blaha, Michael J.
    CURRENT OPINION IN CARDIOLOGY, 2013, 28 (05) : 554 - 560
  • [23] Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
    Byrne, Paula
    Cullinan, John
    Smith, Amelia
    Smith, Susan M.
    BMJ OPEN, 2019, 9 (04):
  • [24] Comparison Shopping: Guidelines for Statins for Primary Prevention of Cardiovascular Disease
    Mancini, G. B. John
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) : 145 - 146
  • [25] Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
    Erickson, Kevin F.
    Japa, Sohan
    Owens, Douglas K.
    Chertow, Glenn M.
    Garber, Alan M.
    Goldhaber-Fiebert, Jeremy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (12) : 1250 - 1258
  • [26] Primary prevention of cardiovascular disease with statins: cautionary notes
    Goldstein, M. R.
    Mascitelli, L.
    Pezzetta, F.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2009, 102 (11) : 817 - 820
  • [27] Statins for the Primary Prevention of Coronary Heart Disease
    Li, Min
    Wang, Xiaoli
    Li, Xinyi
    Chen, Heqing
    Hu, Yeyin
    Zhang, Xiatian
    Tang, Xiaoyi
    Miao, Yaodong
    Tian, Guihua
    Shang, Hongcai
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [28] Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study
    Ramos, Rafel
    Comas-Cufi, Marc
    Marti-Lluch, Ruth
    Ballo, Elisabeth
    Ponjoan, Anna
    Alves-Cabratosa, Lia
    Blanch, Jordi
    Marrugat, Jaume
    Elosua, Roberto
    Grau, Maria
    Elosua-Bayes, Marc
    Garcia-Ortiz, Luis
    Garcia-Gil, Maria
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [29] Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease
    Lardizabal, Joel A.
    Deedwania, Prakash
    CARDIOLOGY CLINICS, 2011, 29 (01) : 87 - +
  • [30] Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index
    Yoo, Joonsang
    Jeon, Jimin
    Baik, Minyoul
    Kim, Jinkwon
    JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2024, 14 (03) : 710 - 719